Latest in laser generation

Article

Breaking news from the floor of ESCRS

SCHWIND has launched the new AMARIS 750S laser system, a further development of the AMARIS portfolio of laser systems, now with a pulse frequency of 750 Hz. According to the company, this system will benefit patients with its extremely short treatment time, which is combined with safety features that include the six-dimensional, active 1050 Hz eye tracking.

The system was showcased at a symposium during the congress, where experts shared their experiences of using the new system. Maria C. Arbelaez, from the Muscat Eye Laser Center, Oman, presented the results of a one-month LASIK study of 225 eyes.

The system was used for LASIK aberration-free treatments for myopia and myopic astigmatism. For the type of procedure used, the ablation times per dioptre were found to be much lower compared to the market median. After one month 85% of treated eyes have achieved the planned refractive outcome with a minimal deviation of a quarter of a dioptre and 100% were within half a dioptre. Despite the short follow-up time, the study concluded that results so far imply the recovery after treatment is very short and that the system shows excellent performance.

Alfred Vogeland Thomas Kohnen presented a new concept laser system that the company claims could mean a paradigm shift in refractive and therapeutic corneal surgery; the multifunctional and mobile SmartTech Laser. The laser system is based on nanosecond laser technology and uses the principle of plasma creation for separation of the corneal tissue. The focal spot is reported to be one-third the size of standard femtosecond lasers, which the studies found, along with the short wavelength in the UV range and aberration-free optical system, resulted in extreme precision.

Further details of the symposium will appear in a future issue of Ophthalmology Times Europe.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.